Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD)-Reference-Cited by-同舟云学术

Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD)

Published:2018-08-22 Issue:8 Volume:2018 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Ruospo Marinella¹,Palmer Suetonia C²,Natale Patrizia¹³,Craig Jonathan C⁴⁵,Vecchio Mariacristina⁶,Elder Grahame J⁷⁸,Strippoli Giovanni FM¹³⁴⁹¹⁰

Affiliation:

1. Diaverum; Medical Scientific Office; Lund Sweden

2. University of Otago Christchurch; Department of Medicine; 2 Riccarton Ave PO Box 4345 Christchurch New Zealand 8140

3. University of Bari; Department of Emergency and Organ Transplantation; Bari Italy

4. The Children's Hospital at Westmead; Cochrane Kidney and Transplant, Centre for Kidney Research; Westmead NSW Australia 2145

5. Flinders University; College of Medicine and Public Health; Adelaide SA Australia 5001

6. Danone Research; RD 128 Palaiseau Cedex France 91767

7. Westmead Hospital; Department of Renal Medicine; Westmead NSW Australia 2145

8. Garvan Institute of Medical Research; Osteoporosis and Bone Biology Division; Darlinghurst NSW Australia 2010

9. Diaverum Academy; Bari Italy

10. The University of Sydney; Sydney School of Public Health; Sydney Australia

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006023.pub3/epdf/full

Reference518 articles.

1. Comparative efficacy of sevelamer hydrochloride versus calcium acetate on bone biomarkers in patients with end stage renal disease on hemodialysis;Ahmed;Pakistan Journal of Medical & Health Sciences,2014

2. Effect of sevelamer hydrochloride (PB-94) on hyperphosphatemia in Japanese hemodialysis (HD) patients [abstract no: A2940];Akizawa;Journal of the American Society of Nephrology,2000

3. Effects of PB-94 (sevelamer hydrochloride), a phosphate binder, on the treatment of hyperphosphatemia in hemodialysis patients - a randomized, open label, dose titration study of PB-94 versus caltan® tablet 500 (calcium carbonate) [abstract];Kinugasa;Journal of the American Society of Nephrology,2001

4. Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia;Akizawa;Therapeutic Apheresis & Dialysis,2014

5. Bixalomer in hyperphosphatemic patients with chronic kidney disease not on dialysis: phase 3 randomized trial;Akizawa;Therapeutic Apheresis & Dialysis,2016

Cited by 107 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Persistent uncertainties in optimal treatment approaches of secondary hyperparathyroidism and hyperphosphatemia in patients with chronic kidney disease;Current Osteoporosis Reports;2024-08-19

2. Reducing serum phosphate level: how low should we go?;Kidney International;2024-08

3. Current therapeutic approach of chronic kidney disease‐mineral and bone disorder;Therapeutic Apheresis and Dialysis;2024-06-19

4. Oral phosphate binders and incident osteoporotic fracture in patients on dialysis;Nephrology Dialysis Transplantation;2024-06-17

5. Phosphate as an adjunct to calcium in promoting coronary vascular calcification in chronic inflammatory states;eLife;2024-06-12